Research programme: anti-R7V monoclonal antibody - Dyax/URRMA
Latest Information Update: 07 Jun 2007
Price :
$50 *
At a glance
- Originator Dyax; URRMA Biopharma
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 29 Oct 2003 Preclinical trials in HIV infections treatment in Canada (unspecified route)
- 29 Oct 2003 Preclinical trials in HIV infections treatment in USA (unspecified route)